Heidi Anderson Hupe — investor profile photo

Heidi Anderson Hupe

Portfolio Chief Growth Officer | Scaling AI + Healthcare Platforms | President & Chief Revenue Officer | Board Director | DTC, B2B

📍 United States🔄 Updated November 2026💼 2 investments📅 5 years investing🗓 Last invested Oct 2021
Operator-angel🌍 United States
2
Total investments
0
Early stage
0
Mid stage
0
Late stage
5y
Years active

Portfolio

0 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
No investments found
Experience · 3 entries
All (3)
Investments (2)
Founder (1)
Board (1)
2021
Investor
Oct 2021
Nox Health is a global leader in sleep diagnostics and value-based care on a mission to improve the health of people with chronic conditions. Our diagnostic devices are used more than two million times annually in more than 50 countries, and our value-based, outcomes-focused sleep care management program now covers more than a million employees. Headquartered in Atlanta, Georgia, and with operations in Reykjavík, Iceland and Denver, Colorado, Nox Health’s delivery of sleep care is unmatched with accurate sleep diagnostics, comprehensive, value-based sleep care management and rigorous outcomes measurement. For more information on Nox Health, please visit www.noxhealth.com.
Board Member
Jun 2021
Solis Mammography is an innovation-driven healthcare provider that has been dedicated to helping women achieve and maintain breast health and peace of mind for more than 35 years. Headquartered in Addison, Texas, Solis Mammography operates more than 100 centers in 13 markets, including Dallas-Fort Worth, Houston, Denver, Phoenix, Philadelphia, Columbus, Nashville, Greensboro, Miami, Fort Lauderdale, and through its affiliated brands Washington Radiology and Progressive Radiology, in greater Washington, D.C., Northern Virginia and Eastern Maryland. The company operates both wholly owned centers and multiple joint venture partnerships with large hospital systems and prominent academic medical institutions. Solis Mammography collaborates with medical technology companies, professional medical societies and academic partners on clinical research that advances its mission of earliest stage breast cancer detection. The company’s latest service offering, Mammo+Plus, is a personalized, image-based assessment that uses a sophisticated Artificial Intelligence algorithm to calculate a predictive score for a patient’s one-year risk of getting breast cancer.
2020
Executive Advisor | Consultant to Founders and Boards
Jan 2020
Investor lists
Lists that match Heidi's portfolio